These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse. Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411 [TBL] [Abstract][Full Text] [Related]
29. 6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat. Rangel-Barajas C; Silva I; García-Ramírez M; Sánchez-Lemus E; Floran L; Aceves J; Erlij D; Florán B Neuropharmacology; 2008 Oct; 55(5):704-11. PubMed ID: 18588904 [TBL] [Abstract][Full Text] [Related]
30. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Stockwell KA; Virley DJ; Perren M; Iravani MM; Jackson MJ; Rose S; Jenner P Exp Neurol; 2008 May; 211(1):172-9. PubMed ID: 18321484 [TBL] [Abstract][Full Text] [Related]
31. Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. Branchi I; D'Andrea I; Armida M; Cassano T; Pèzzola A; Potenza RL; Morgese MG; Popoli P; Alleva E J Neurosci Res; 2008 Jul; 86(9):2050-61. PubMed ID: 18335518 [TBL] [Abstract][Full Text] [Related]
32. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism. Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163 [TBL] [Abstract][Full Text] [Related]
33. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364 [TBL] [Abstract][Full Text] [Related]
34. [Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model]. Katunina EA; Samoĭlova EV; Val'dman EA; Nerobkova LN; Voronina TA; Avakian GN Eksp Klin Farmakol; 2004; 67(2):16-8. PubMed ID: 15188753 [TBL] [Abstract][Full Text] [Related]
35. Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model. Philippens IH; Wubben JA; Finsen B; 't Hart BA J Neuroimmune Pharmacol; 2013 Jun; 8(3):715-26. PubMed ID: 23504289 [TBL] [Abstract][Full Text] [Related]
36. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732 [TBL] [Abstract][Full Text] [Related]
37. Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission. Cadoni C; Valentini V; Di Chiara G J Neurochem; 2008 Aug; 106(4):1586-93. PubMed ID: 18513369 [TBL] [Abstract][Full Text] [Related]
39. The footfault test as a screening tool in the 6-hydroxydopamine rat model of Parkinson's disease. Silvestrin RB; de Oliveira LF; Batassini C; Oliveira A; e Souza TM J Neurosci Methods; 2009 Mar; 177(2):317-21. PubMed ID: 19026686 [TBL] [Abstract][Full Text] [Related]
40. Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice. Laloux C; Derambure P; Houdayer E; Jacquesson JM; Bordet R; Destée A; Monaca C J Sleep Res; 2008 Mar; 17(1):101-10. PubMed ID: 18275560 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]